News

How HIV spreads from DCs
Enlarge image

ResearchSpainSwitzerlandGermany

How HIV spreads from DCs

20.12.2012 - Spanish researchers have unraveled how HIV disperses throughout the body – and can block the process before it occurs.

In a previous publication with Swiss and German virologists, researchers headed by Nuria Izquierdo-Useros from the AIDS Research Institute IrsiCaixa in Barcelona discovered that the HI virus uses specific membrane lipids called gangliosides on their surface to enter dendritic cells (DCs) by modifying membrane fluidity. Based on these findings, they tried to make the DC’s membrane more rigid by using a dihydroceramide desaturase (Des-1) blocker, which they have filed for patent. The new approach seems promising because HIV has first to enter DCs to be passed to their target cells, the CD4 T lymphocytes, in a process termed trans-infection. Now, the Spanish team has identified the molecule on the surface of DCs that recognises and binds the gangliosides and allows HIV to be taken up by dendritic cells and transmitted to CD4 cells. The new study is published in the open access journal PLOS Biology.

In order to identify the precise molecule located on the membrane of the dendritic cells capable of capturing HIV, the researchers studied one family of proteins that are present on the surface of these cells, called Siglecs. It is known that these proteins bind to the gangliosides on the HIV surface. In the laboratory, they mixed the virus with dendritic cells that displayed different quantities of Siglec-1, and found that a higher quantity of Siglec-1 led to those dendritic cells capturing more HIV, which in turn allowed for enhanced transmission of HIV to CD4 T lymphocytes, a process called trans-infection.

The team then tried inhibiting the Siglec-1 protein. They found that the dendritic cells lost their capacity to capture HIV and, importantly, they also lost their ability to transfer HIV to CD4 T lymphocytes. With all these data, the scientists concluded that Siglec-1 is the molecule responsible for HIV entrance into the dendritic cells, and could therefore become a new therapeutic target. "We had the key and now we have found a lock," explains Javier Martínez-Picado. "Now we are already working on the development of a drug that could block this process to improve the efficacy of the current existing treatments against AIDS".

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/how-hiv-spreads-from-dcs.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.39 CHF21.87%
  • THERAMETRICS0.07 CHF16.67%
  • SANTHERA97.50 CHF5.98%

FLOP

  • 4SC0.78 EUR-8.24%
  • ADDEX3.36 CHF-5.62%
  • BIOFRONTERA1.95 EUR-2.50%

TOP

  • CYTOS0.39 CHF77.3%
  • ADDEX3.36 CHF44.2%
  • BB BIOTECH253.50 EUR28.1%

FLOP

  • ACTELION99.25 CHF-16.3%
  • BIOFRONTERA1.95 EUR-15.2%
  • 4SC0.78 EUR-13.3%

TOP

  • SANTHERA97.50 CHF2355.9%
  • BB BIOTECH253.50 EUR110.1%
  • FORMYCON12.40 EUR60.0%

FLOP

  • CYTOS0.39 CHF-88.1%
  • 4SC0.78 EUR-51.6%
  • MOLOGEN5.79 EUR-50.1%

No liability assumed, Date: 26.01.2015